See the DrugPatentWatch profile for sapropterin

Yes, Sapropterin is a treatment targeted towards Phenylketonuria (PKU), a genetic disorder that results in the buildup of phenylalanine (Phe) amino acid in the body due to an inability to break it down [1]. This buildup can lead to harmful effects on the brain. Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), a cofactor that helps break down Phe in the body [1].

According to DrugPatentWatch.com, BioMarin Pharmaceutical Inc. holds the patent for Sapropterin under the brand name Kuvan [2]. The patent for Kuvan expired in 2020, but BioMarin was granted a patent extension until 2030 [2].

In summary, Sapropterin is a treatment for PKU, a genetic disorder that results in the buildup of Phe in the body. Sapropterin is a synthetic form of BH4, a cofactor that helps break down Phe in the body. BioMarin Pharmaceutical Inc. holds the patent for Sapropterin under the brand name Kuvan.

Sources:

1. National Institutes of Health. (2021). Phenylketonuria. Genetics Home Reference. <https://medlineplus.gov/genetics/condition/phenylketonuria/>
2. DrugPatentWatch.com. (2021). Kuvan (Sapropterin Dihydrochloride) Drug Patent Expiration. <https://www.drugpatentwatch.com/drugs/kuvan.html>